Sleep motor activity in amyotrophic lateral sclerosis
Objective: To analyze quantitatively and with the most recent and advanced tools the presence of periodic leg movements during sleep (PLMS) PLMS and/or REM sleep…Prevalence of restless legs syndrome in an atypical Parkinson’s disease population
Objective: The aim of this study was to determine the prevalence of Restless Legs Syndrome (RLS) in patients with Multiple Systems Atrophy (MSA), Corticobasilar Degeneration…Augmentation and impulse control disorders in restless legs syndrome – Coexistence or association?
Objective: To assess the frequency of impulse control disorders (ICDs) in patients with restless legs syndrome (RLS) with and without augmentation under dopaminergic therapy. Background:…Depression and apathy in restless legs syndrome
Objective: We examined the prevalence of mood disorders (depression, apathy) and its' characteristics. Moreover, to investigate pathophysiology of the mood disorders in the patient in…Duodopa for the treatment of severe restless legs syndrome
Objective: To describe the outcome of a patient with restless legs syndrome (RLS) and augmentation phenomena that was treated with Duodopa in continuous infusion. Background:…Systematic review and meta-analysis of randomized controlled trials to evaluate placebo response in restless legs syndrome
Objective: To quantify the magnitude of the placebo response in restless legs syndrome (RLS). Background: RLS is a common sensorimotor disorder characterized by an urge…A homozygous loss-of-function mutation in DNAJA3 causes hereditary motor and sensory neuropathy with spastic paraplegia (HMSN type V)
Objective: To identify a genetic cause for hereditary motor and sensory neuropathy with spastic paraplegia (HMSN type V). Background: Hereditary spastic paraplegia (HSP) constitutes a…A phase 3, placebo-controlled study with an open-label extension: Sustained incobotulinumtoxinA efficacy in upper-limb post-stroke spasticity over 48 weeks
Objective: To assess the efficacy and safety of incobotulinumtoxinA for upper-limb post-stroke spasticity. Background: Botulinum toxin injections are a recommended therapy for limb spasticity. We…Safety and efficacy of escalating doses of incobotulinumtoxinA (400-800U): Increasing improvements in disability due to multifocal upper- and lower-limb spasticity
Objective: To assess the safety and efficacy of escalating incobotulinumtoxinA doses (400-800U) in patients with spasticity. Background: Botulinum toxin treatment at higher doses than currently…SPAsticity in PractiCE (SPACE) – An international, observational study of botulinum toxin type A in spasticity
Objective: To collect real-world routine clinical practice data on effectiveness, safety, and quality of life (QoL) for botulinum toxin type A (BoNT-A) treatment of focal…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.